Autoimmune Diseases  >>  Veltucyn (veltuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Veltucyn (veltuzumab) / Gilead
VELVET, NCT01390545 / 2010-022378-15: , a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Checkmark Trial termination [VELVET]
Oct 2012 - Oct 2012: Trial termination [VELVET]
Terminated
2
300
US, Canada, Europe, RoW
Veltuzumab
Takeda
Rheumatoid Arthritis
10/12
10/12

Download Options